In 2024–25, the Medicines and Healthcare products Regulatory Agency (MHRA) completed 353 GMP inspections, highlighting the UK’s continued focus on pharmaceutical manufacturing quality and regulatory compliance. As regulatory expectations continue to evolve, good manufacturing practice in UK has become more than a legal requirement, it is a competitive advantage for pharmaceutical manufacturers preparing for MHRA inspections. Understanding Good Manufacturing Practices (GMP) helps organizations strengthen quality systems, reduce compliance risks, and improve inspection readiness. This guide explains the latest MHRA expectations, common inspection findings, and practical strategies to achieve GMP compliance in the UK in 2026.
Table of Contents
What Is Good Manufacturing Practice in UK?
Good manufacturing practice in UK defines the quality standards that pharmaceutical manufacturers must follow to produce safe, effective, and consistent medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates licensed manufacturers through a risk-based inspection program and verifies compliance with UK GMP requirements before and after products reach the market. Moreover, the UK GMP framework remains closely aligned with internationally recognized GMP principles, allowing manufacturers to support global regulatory expectations while maintaining high standards for product quality, patient safety, and data integrity.
How MHRA GMP Inspections Evaluate Pharmaceutical Manufacturers
The MHRA uses a risk-based inspection approach to evaluate whether pharmaceutical manufacturers consistently meet GMP requirements. Inspectors review critical quality systems, including the Pharmaceutical Quality System (PQS), documentation, data integrity, validation, equipment qualification, contamination control, and personnel training. In addition, they classify inspection findings according to their potential impact on product quality and patient safety before making regulatory decisions. Therefore, manufacturers that maintain robust quality systems, complete documentation, and effective CAPA programs are better prepared for successful MHRA inspections.
This infographic illustrates the complete MHRA GMP inspection process, from initial risk assessment to the final regulatory decision, helping pharmaceutical manufacturers understand how inspectors evaluate GMP compliance at every stage.
Core GMP Systems Reviewed During MHRA Inspections
MHRA inspectors focus on the GMP systems that have the greatest impact on product quality, patient safety, and regulatory compliance. Therefore, manufacturers should understand how each system supports inspection readiness and reduces compliance risks.
The following sections highlight the key quality areas that inspectors assess during every GMP inspection:
- Pharmaceutical Quality System (PDF)
- Documentation and Data Integrity (PDF)
- Qualification and Process Validation (PDF)
- Premises, Equipment and Contamination Control (PDF)
Pharmaceutical Quality System (PDF)
A robust Pharmaceutical Quality System (PQS) supports consistent product quality and GMP compliance. MHRA inspectors assess quality management, CAPA, and change control.
Documentation and Data Integrity (PDF)
Reliable documentation demonstrates GMP compliance. MHRA also verifies that data remains complete, accurate, and traceable.
Qualification and Process Validation (PDF)
Qualification and validation confirm that equipment and processes perform consistently. Inspectors review validation evidence throughout the product lifecycle.
Download PIC/S Guide to GMP – Annex 15: Qualification and Validation Here
Premises, Equipment and Contamination Control (PDF)
Effective facility and equipment controls reduce contamination risks. MHRA evaluates environmental controls and equipment readiness during inspections.
Download PIC/S Guide to GMP – Annex 1: Manufacture of Sterile Medicinal Products Here
Common MHRA Inspection Findings and CAPA Priorities
MHRA inspections frequently identify deficiencies that weaken GMP compliance and increase regulatory risk. The most common findings involve documentation, data integrity, quality systems, validation, and contamination control. Therefore, manufacturers should focus on effective Corrective and Preventive Actions (CAPA) that address the root cause of each issue instead of applying temporary fixes. A structured CAPA program not only reduces repeat observations but also strengthens inspection readiness and supports long-term compliance.
This infographic highlights the most common MHRA GMP inspection findings and the CAPA strategies that help pharmaceutical manufacturers strengthen compliance and improve inspection readiness.
UK GMP Requirements Compared with MHRA Inspection Expectations
Meeting UK GMP requirements does not automatically guarantee a successful MHRA inspection. While manufacturers must comply with regulatory standards, MHRA inspectors place greater emphasis on how these requirements perform in daily operations. Therefore, organizations should focus on the quality systems that have the greatest impact on inspection outcomes.
The table below compares the four UK GMP areas that receive the highest level of attention during MHRA inspections.
| UK GMP Requirement | MHRA Inspection Focus |
|---|---|
|
Pharmaceutical Quality System (PQS) |
Quality culture, CAPA effectiveness, change control, and management oversight |
|
Documentation & Data Integrity |
ALCOA+ principles, audit trails, record accuracy, and data governance |
|
Qualification & Process Validation |
IQ/OQ/PQ evidence, validation lifecycle, and ongoing process verification |
|
Premises, Equipment & Contamination Control |
Facility design, equipment qualification, environmental monitoring, and contamination prevention |
Final Words
MHRA continues to strengthen its regulatory oversight across the UK pharmaceutical sector. In 2024–25, the agency completed 855 GxP inspections, demonstrating its continued focus on quality, data integrity, and patient safety across regulated manufacturing activities. As inspection expectations continue to evolve, good manufacturing practice in UK requires more than regulatory compliance. Manufacturers that invest in robust quality systems, proactive risk management, and continuous inspection readiness will be better positioned to achieve long-term compliance and maintain confidence in a highly regulated industry.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
MHRA uses a risk-based inspection program. The inspection frequency depends on the manufacturer’s compliance history, product risk, previous inspection findings, and operational changes.
Most MHRA observations relate to weaknesses in documentation, data integrity, quality systems, validation, and CAPA effectiveness. Manufacturers can reduce these risks by maintaining robust GMP processes and complete records.
The best preparation includes maintaining an effective Pharmaceutical Quality System, completing internal GMP audits, resolving deviations through effective CAPA, keeping validation documents up to date, and ensuring personnel receive ongoing GMP training.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.